Ignite Creation Date:
2024-05-06 @ 2:36 PM
Last Modification Date:
2024-10-26 @ 1:34 PM
Study NCT ID:
NCT04371978
Status:
TERMINATED
Last Update Posted:
2021-06-02
First Post:
2020-04-30
Brief Title:
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
Sponsor:
Rabin Medical Center
Organization:
Rabin Medical Center
Study Overview
Official Title:
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
Status:
TERMINATED
Status Verified Date:
2021-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
End of COVID-19 outbreak in Israel
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The coronavirus disease 2019 COVID-19 is an emerging pandemic in 2020 caused by a novel coronavirus named SARS-CoV2 Diabetes confers a significant additional risk for COVID-19 patients Dipeptidyl peptidase 4 DPP-4 is a transmembrane glycoprotein expressed ubiquitously in many tissues In addition to its effect on glucose levels DPP-4 has various effects on the immune system and several diseases including lung diseases This trial aims to assess the safety and efficacy of linagliptin a DPP-4 inhibitor in the treatment of COVID-19 The trial will be randomized without blinding with one are treated by insulin only for glucose balance and the other by insulin and linagliptin The trial will assess the effects of linagliptin on different measures of COVID-19 recovery
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None